Events and Presentations
Those parties interested in participating via telephone may register here to receive dial-in numbers and a unique PIN to join the call. Otherwise please use the webcast link.
Session: Late-Breaker Session 3
Abstract Title: Efficacy and Safety of Pemvidutide in the Treatment of Adults with Alcohol Use Disorder: Results from RECLAIM, a 24-Week Phase 2 Randomized Double-Blind Placebo-Controlled Trial
Speaker: Henry R. Kranzler, M.D.
Session: Clinical Trial Pipeline for MASH 2026
Abstract Title: Pemvidutide Treatment Results in Concurrent Reductions in Multiple Non-Invasive Tests for Hepatic Inflammation and Fibrosis: 48-Week Responder Analyses of the IMPACT Phase 2b Trial in Metabolic Dysfunction-Associated Steatohepatitis
Speaker: Dr. Naim Alkhouri
Session: MASLD/MASH Therapeutics
Abstract Title: Gastrointestinal Tolerability of Pemvidutide Without Dose Titration in Patients with Metabolic Dysfunction-Associated Steatohepatitis from the Phase 2b IMPACT Trial
Speaker: Dr. Mazen Noureddin
Session: Industry Review Showcase
Abstract Title: Pemvidutide Treatment Reduces Alcohol Intake in a Lean Golden Syrian Hamster Model
Speaker: John J. Suschak
